Efficacy in Humans : Gastrointestinal Benefits : For individuals with gut issues, oral BPC-157 may provide general anti-inflammatory benefits
CagriSema side effects In the REDEFINE 1 trial, gastrointestinal adverse events affected 79.6% of participants receiving CagriSema, compared to 39.9% in the placebo group
Tesamorelin 1 , a synthetic growth hormone-releasing hormone (GHRH) analog, specifically reduces visceral adiposity by stimulating growth hormone (GH) release from the pituitary gland, leading to decreased abdominal fat in individuals with HIV-associated lipodystrophy
The end of the small intestine is where the absorption of vitamin B12 takes place
A study could investigate whether BPC 157 can reduce markers of liver or kidney stress during a course of potent antibiotics
There are though some patients who want to use higher doses and more frequent injections than recommended in NICE guidelines